1型糖尿病视网膜病变循证筛查频率研究
该研究利用糖尿病控制与并发症试验(DCCT)及其后续流行病学糖尿病干预与并发症(EDIC)研究的视网膜照片,采用马尔可夫模型,按患者初始视网膜病变程度及糖化血红蛋白水平制定个体化筛查间隔;结果显示该方案在20年间使眼科检查频率较常规年度检查降低58%,且未延误临床显著疾病的诊断。
要点
- 无视网膜病变者筛查间隔4年,轻度病变3年,中度病变6个月,重度非增殖性病变3个月。
- 无视网膜病变进展至增殖性糖尿病视网膜病变或临床显著黄斑水肿的风险与糖化血红蛋白水平密切相关。
- 个体化筛查方案较年度常规检查降低58%的检查频率,且未延误临床显著疾病的诊断。
核心结论
- 基于患者当前视网膜病变程度和糖化血红蛋白水平建立的个体化视网膜病变筛查模型,在未延误临床显著疾病诊断的前提下降低了眼科检查频率。
研究设计与样本
- 利用DCCT/EDIC研究的视网膜照片(检查间隔6个月至4年),采用马尔可夫模型分析不同初始视网膜病变程度患者进展至增殖性糖尿病视网膜病变或临床显著黄斑水肿的可能性,模型纳入已确认的视网膜病变进展危险因素。
主要发现
- 在无视网膜病变患者中,4年筛查间隔内进展至增殖性糖尿病视网膜病变或临床显著黄斑水肿的概率约为5%。
- 在轻度视网膜病变患者中,3年筛查间隔内该概率约为5%;中度视网膜病变患者6个月间隔内约为5%;重度非增殖性糖尿病视网膜病变患者3个月间隔内约为5%。
- 糖化血红蛋白水平为6%的患者5年内从无视网膜病变进展至增殖性糖尿病视网膜病变或临床显著黄斑水肿的风险为1.0%,而糖化血红蛋白水平为10%的患者3年内该风险为4.3%。
- 20年期间,该循证筛查方案的检查频率较常规年度检查降低58%,并带来可观的费用节省。
关键数值与推荐
- 无视网膜病变:筛查间隔4年;轻度非增殖性视网膜病变:3年;中度非增殖性视网膜病变:6个月;重度非增殖性视网膜病变:3个月。
- 糖化血红蛋白6%:5年内进展风险1.0%;糖化血红蛋白10%:3年内进展风险4.3%。
- 20年间检查频率较常规年度检查降低58%。
临床怎么用
- 作者提出可根据患者当前视网膜病变程度和糖化血红蛋白水平制定个体化视网膜病变筛查时间表,以降低检查频率而不延误临床显著疾病的诊断。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients who have had type 1 diabetes for 5 years, current recommendations regarding screening for diabetic retinopathy include annual dilated retinal examinations to detect proliferative retinopathy or clinically significant macular edema, both of which require timely intervention to preserve vision. During 30 years of the Diabetes Control and Complications Trial (DCCT) and its longitudinal follow-up Epidemiology of Diabetes Interventions and Complications (EDIC) study, retinal photography was performed at intervals of 6 months to 4 years. METHODS: We used retinal photographs from the DCCT/EDIC study to develop a rational screening frequency for retinopathy. Markov modeling was used to determine the likelihood of progression to proliferative diabetic retinopathy or clinically significant macular edema in patients with various initial retinopathy levels (no retinopathy or mild, moderate, or severe nonproliferative diabetic retinopathy). The models included recognized risk factors for progression of retinopathy. RESULTS: Overall, the probability of progression to proliferative diabetic retinopathy or clinically significant macular edema was limited to approximately 5% between retinal screening examinations at 4 years among patients who had no retinopathy, 3 years among those with mild retinopathy, 6 months among those with moderate retinopathy, and 3 months among those with severe nonproliferative diabetic retinopathy. The risk of progression was also closely related to mean glycated hemoglobin levels. The risk of progression from no retinopathy to proliferative diabetic retinopathy or clinically significant macular edema was 1.0% over 5 years among patients with a glycated hemoglobin level of 6%, as compared with 4.3% over 3 years among patients with a glycated hemoglobin level of 10%. Over a 20-year period, the frequency of eye examinations was 58% lower with our practical, evidence-based schedule than with routine annual examinations, which resulted in substantial cost savings. CONCLUSIONS: Our model for establishing an individualized schedule for retinopathy screening on the basis of the patient's current state of retinopathy and glycated hemoglobin level reduced the frequency of eye examinations without delaying the diagnosis of clinically significant disease. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; DCCT/EDIC ClinicalTrials.gov numbers, NCT00360893 and NCT00360815 .).
引用
- Nathan DM, Bebu I, Hainsworth D, et al. Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes. N Engl J Med. 2017. PMID: 28423305. doi:10.1056/NEJMoa1612836
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。